Hemostatics is developing a novel antifibrinolytic agent to reduce bleeding in life-threatening and disabling haemorrhagic conditions. Thanks to an innovative mechanism of action to inhibit fibrinolysis, our patented preclinical candidate is aiming to address a number of significant unmet medical needs in trauma, surgery, ICH, PPH, GI bleeding and in several bleeding disorders (Rare Diseases).